Jeffrey Strovel
YOU?
Author Swipe
View article: Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Systematic approaches for accurate repurposing of targeted therapies are needed. We developed and aimed to biologically validate our therapy predicting tool (TPT) for the repurposing of targeted therapies for specific tumor types by testin…
View article: Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Raw RPPA data for OVCAR 4.
View article: Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Raw RPPA data for OVCAR 5.
View article: Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
File contains synthesis of CN210, sequences for siRNAs, supplementary tables 1 to 3, supplementary figures 1 through 8 and figure legends.
View article: Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
File contains synthesis of CN210, sequences for siRNAs, supplementary tables 1 to 3, supplementary figures 1 through 8 and figure legends.
View article: Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Systematic approaches for accurate repurposing of targeted therapies are needed. We developed and aimed to biologically validate our therapy predicting tool (TPT) for the repurposing of targeted therapies for specific tumor types by testin…
View article: Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Raw RPPA data for OVCAR 5.
View article: Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Raw RPPA data for OVCAR 4.
View article: Supplementary Figures S6- S12 from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth
Supplementary Figures S6- S12 from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth Open
S6. Evaluation of combined effect of ERGi-USU and AR inhibitors on CaP cell growth, S7. Selective inhibition of ERG positive cancer cells by ERGi-USU in mouse xenograft model, S8. Assessment of effect of RIOK knock down in ERG positive VCa…
View article: Supplementary Figures S1-S5 from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth
Supplementary Figures S1-S5 from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth Open
S1. Comparison and confirmation of ERGi-USU effect on ERG protein, cell growth and gene expression, S2. Antibody based Screening and identification of small molecule inhibitors of the ERG oncoprotein expression, S3. Evaluation of dose-depe…
View article: Supplementary Tables S1 and S2 from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth
Supplementary Tables S1 and S2 from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth Open
S1. PCR primer list for ERG, S2. IC50 values of Inhibition of ERG protein and cell growth of ERGi-USU on established cell panel
View article: Data from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth
Data from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth Open
Oncogenic activation of the ETS-related gene (ERG) by recurrent gene fusions (predominantly TMPRSS2–ERG) is one of the most validated and prevalent genomic alterations present in early stages of prostate cancer. In this study, we sc…
View article: Supplementary Materials and Methods and References from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth
Supplementary Materials and Methods and References from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth Open
Reagents. Antibodies for Immunoblot, methods for qPCR, Tunnel assay and Determination of equilibrium dissociation constant (Kd) of RIOK proteins and Additional references supporting the ERGi-USU manuscript
View article: Supplementary Tables S1 and S2 from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth
Supplementary Tables S1 and S2 from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth Open
S1. PCR primer list for ERG, S2. IC50 values of Inhibition of ERG protein and cell growth of ERGi-USU on established cell panel
View article: Data from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth
Data from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth Open
Oncogenic activation of the ETS-related gene (ERG) by recurrent gene fusions (predominantly TMPRSS2–ERG) is one of the most validated and prevalent genomic alterations present in early stages of prostate cancer. In this study, we sc…
View article: Supplementary Figures S1-S5 from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth
Supplementary Figures S1-S5 from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth Open
S1. Comparison and confirmation of ERGi-USU effect on ERG protein, cell growth and gene expression, S2. Antibody based Screening and identification of small molecule inhibitors of the ERG oncoprotein expression, S3. Evaluation of dose-depe…
View article: Supplementary Materials and Methods and References from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth
Supplementary Materials and Methods and References from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth Open
Reagents. Antibodies for Immunoblot, methods for qPCR, Tunnel assay and Determination of equilibrium dissociation constant (Kd) of RIOK proteins and Additional references supporting the ERGi-USU manuscript
View article: Supplementary Figures S6- S12 from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth
Supplementary Figures S6- S12 from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth Open
S6. Evaluation of combined effect of ERGi-USU and AR inhibitors on CaP cell growth, S7. Selective inhibition of ERG positive cancer cells by ERGi-USU in mouse xenograft model, S8. Assessment of effect of RIOK knock down in ERG positive VCa…
View article: Discovery and anti-tumor activity of 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one (CG13250), a potent, selective and orally bioavailable BET bromodomain inhibitor
Discovery and anti-tumor activity of 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one (CG13250), a potent, selective and orally bioavailable BET bromodomain inhibitor Open
View article: CG223, a novel BET inhibitor, exerts TGF-β1-mediated antifibrotic effects in a murine model of bleomycin-induced pulmonary fibrosis
CG223, a novel BET inhibitor, exerts TGF-β1-mediated antifibrotic effects in a murine model of bleomycin-induced pulmonary fibrosis Open
View article: Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases Open
View article: Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4
Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4 Open
Systematic approaches for accurate repurposing of targeted therapies are needed. We developed and aimed to biologically validate our therapy predicting tool (TPT) for the repurposing of targeted therapies for specific tumor types by testin…
View article: Discovery and lead identification of quinazoline-based BRD4 inhibitors
Discovery and lead identification of quinazoline-based BRD4 inhibitors Open
View article: CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model
CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model Open
Multiple myeloma (MM) is characterized by the clonal proliferation of neoplastic plasma cells. Despite a stream of new molecular targets based on better understanding of the disease, MM remains incurable. Epigenomic abnormalities contribut…
View article: BRD4 Structure–Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536
BRD4 Structure–Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536 Open
A focused library of analogues of the dual PLK1 kinase/BRD4 bromodomain inhibitor BI-2536 was prepared and then analyzed for BRD4 and PLK1 inhibitory activities. Particularly, replacement of the cyclopentyl group with a 3-bromobenzyl moiet…